Alzamend Neuro is trading at $1.23, down 10.87%, with sector pressure a possible contributor; no specific catalyst is confirmed. - No Alzamend Neuro announcement dated October 8 was identified; its investor-relations page lists September 16 as its latest release. - The provided sector context shows XBI down 2.04% during the session. Broad-index declines were modest, and no source directly links the move to a specific catalyst.